Condition: Pulmonary Hypertension (World Health Organization Group 2) · Heart Failure · Sponsor: AstraZeneca
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Research Site | Beverly Hills, California, United States | — |
| Research Site | La Jolla, California, United States | — |
| Research Site | New Haven, Connecticut, United States | — |
| Research Site | Baltimore, Maryland, United States | — |
| Research Site | St Louis, Missouri, United States | — |
| Research Site | Omaha, Nebraska, United States | — |
| Research Site | Rock Hill, South Carolina, United States | — |
| Research Site | Linz, Austria | — |
| Research Site | Vienna, Austria | — |
| Research Site | Edmonton, Alberta, Canada | — |
| Research Site | Vancouver, British Columbia, Canada | — |
| Research Site | Halifax, Nova Scotia, Canada | — |
+ 48 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05737940